ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication for 30th AGM05-07-2024
05-07-2024
Zydus Lifesciences Hits One-Month High As FDA Approves Its Hypertension Drug
The stock rose as much as 4.53% during the day to Rs 1,144.90 apiece on the NSE.04-07-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Closure of Trading Window
Intimation for Trading Window closure25-06-2024
F&O Query: Should you sell Zydus Lifesciences call option?
Only a decisive break of the base at 1,000 can turn the trend bearish25-06-2024
Nepal's drug regulator bans sale of Indian antibiotic over quality issues
Zydus Lifesciences said the reports were 'misleading and erroneous'19-06-2024
Zydus Lifesciences Gets Tentative Approval From US FDA For New Drug
The Azilsartan Medoxomil and Chlorthalidone tablets are prescribed for the treatment of high blood pressure.14-06-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under reg. 39(3) of the SEBI (LODR) Regulations, 201511-06-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under reg. 39(3) of the SEBI (LODR) Regulations, 201507-06-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under SEBI (PIT) Regulations, 201504-06-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under reg. 39(3) of the SEBI (LODR) Regulations, 201528-05-2024